Enhanced mitochondrial activity sensitized Nalm6 to panobinostat. (A) ROS quantification in Nalm6 treated with control or 31.25 mM rosiglitazone for 24 and 48 hours were evaluated by DCFH-DA staining. (B) Membrane potential in Nalm6 treated with control or 31.25 mM rosiglitazone for 24 and 48 hours were evaluated by TMRM staining. (C) Nalm6 were treated with control, 10 nM panobinostat alone, 62.5 μM rosiglitazone alone, and10 nM panobinostat combined with 62.5 μM rosiglitazone for 24 hours. Apoptosis cells were detected by Annexin V-APC (Allophycocyanin) staining using flow cytometry. (D) Nalm6 cells were treated with control, 10 nM panobinostat alone, 62.5 μM rosiglitazone alone, and10 nM panobinostat combined with 62.5 μM rosiglitazone for 72 hours. The MTT assay was used to analyze the relative viability. Data represent mean ± SD (n = 3). Data with statistical significance are as indicated: **P < .01, ***P < .005, ****P < .001.